• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resolution of metastatic cutaneous Crohn's disease with upadacitinib monotherapy.

作者信息

Burningham Kevin M, Verma Kritin K, Patel Anisha B, Tyring Stephen K

机构信息

Center for Clinical Studies, Ltd., Webster, Texas.

Texas Tech University Health Sciences Center School of Medicine, Lubbock, Texas.

出版信息

JAAD Case Rep. 2024 Mar 4;46:81-84. doi: 10.1016/j.jdcr.2024.02.017. eCollection 2024 Apr.

DOI:10.1016/j.jdcr.2024.02.017
PMID:38577495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10992270/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/a92879ebbabf/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/c53862950fe5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/4e7c89f1d967/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/d31c2175c467/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/a92879ebbabf/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/c53862950fe5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/4e7c89f1d967/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/d31c2175c467/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53d4/10992270/a92879ebbabf/gr4.jpg

相似文献

1
Resolution of metastatic cutaneous Crohn's disease with upadacitinib monotherapy.用乌帕替尼单药治疗转移性皮肤克罗恩病取得缓解。
JAAD Case Rep. 2024 Mar 4;46:81-84. doi: 10.1016/j.jdcr.2024.02.017. eCollection 2024 Apr.
2
Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: A case report.乌帕替尼成功治疗泛发性斑秃合并克罗恩病：一例报告
SAGE Open Med Case Rep. 2023 Mar 21;11:2050313X231160914. doi: 10.1177/2050313X231160914. eCollection 2023.
3
Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study.Upadacitinib 治疗克罗恩病肠道黏膜的 Janus 激酶 1 抑制的细胞特异性机制的随机对照试验亚研究：CELEST 研究的分析。
Inflamm Bowel Dis. 2021 Nov 15;27(12):1999-2009. doi: 10.1093/ibd/izab116.
4
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.在健康受试者和类风湿关节炎、克罗恩病、溃疡性结肠炎或特应性皮炎受试者中的乌帕替尼药代动力学：I 期和 II 期临床试验的群体分析。
J Clin Pharmacol. 2020 Apr;60(4):528-539. doi: 10.1002/jcph.1550. Epub 2019 Nov 7.
5
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.乌帕替尼治疗对中度至重度克罗恩病患者的生活质量和工作生产力的改善：来自 2b 期的证据。
Adv Ther. 2021 May;38(5):2339-2352. doi: 10.1007/s12325-021-01660-7. Epub 2021 Mar 23.
6
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.多中心真实世界中乌帕替尼治疗克罗恩病的经验。
J Crohns Colitis. 2023 Apr 19;17(4):504-512. doi: 10.1093/ecco-jcc/jjac157.
7
Upadacitinib for the treatment of moderate-to-severe Crohn's disease.乌帕替尼治疗中重度克罗恩病。
Immunotherapy. 2024 Apr;16(6):345-357. doi: 10.2217/imt-2023-0293. Epub 2024 Feb 16.
8
Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center.乌帕替尼治疗克罗恩病安全有效：来自三级中心的真实世界数据
Dig Dis Sci. 2023 Feb;68(2):385-388. doi: 10.1007/s10620-022-07582-w. Epub 2022 Jun 13.
9
Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease.乌帕替尼使一名难治性克罗恩病儿科患者迅速实现临床缓解
Inflamm Bowel Dis. 2023 Jul 5;29(7):1175-1176. doi: 10.1093/ibd/izad048.
10
Do JAK inhibitors have a realistic future in treating Crohn's disease?JAK抑制剂在治疗克罗恩病方面有现实的前景吗？
Expert Rev Clin Immunol. 2022 Mar;18(3):181-183. doi: 10.1080/1744666X.2022.2020101. Epub 2021 Dec 31.

本文引用的文献

1
Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.Janus 激酶抑制剂在炎症性皮肤疾病中的超适应证使用。
J Drugs Dermatol. 2023 Dec 1;22(12):1183-1190. doi: 10.36849/JDD.7500.
2
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.乌帕替尼诱导缓解和维持治疗克罗恩病。
N Engl J Med. 2023 May 25;388(21):1966-1980. doi: 10.1056/NEJMoa2212728.
3
A Meta-Analysis Evaluating the Effectiveness and Safety of Upadacitinib in Treating Rheumatoid Arthritis in Patients With Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs.
一项评估乌帕替尼在对改善病情抗风湿药物反应不足的类风湿关节炎患者中治疗有效性和安全性的荟萃分析。
Cureus. 2023 Jan 30;15(1):e34384. doi: 10.7759/cureus.34384. eCollection 2023 Jan.
4
Metastatic Crohn's disease: an underestimated entity.转移性克罗恩病：一个被低估的实体。
J Dtsch Dermatol Ges. 2021 Jul;19(7):973-982. doi: 10.1111/ddg.14447. Epub 2021 May 7.
5
Cutaneous manifestations of metastatic Crohn's disease.转移性克罗恩病的皮肤表现。
Pediatr Dermatol. 2018 Sep;35(5):566-574. doi: 10.1111/pde.13565. Epub 2018 Jun 28.
6
Metastatic Crohn's Disease: An Approach to an Uncommon but Important Cutaneous Disorder.转移性克罗恩病：一种针对罕见但重要的皮肤疾病的治疗方法。
Biomed Res Int. 2017;2017:8192150. doi: 10.1155/2017/8192150. Epub 2017 Jan 3.
7
Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement.肛周克罗恩病的诊断与治疗：NASPGHAN 临床报告与共识声明。
J Pediatr Gastroenterol Nutr. 2013 Sep;57(3):401-12. doi: 10.1097/MPG.0b013e3182a025ee.
8
Cutaneous manifestations of Crohn's disease.克罗恩病的皮肤表现
J Am Acad Dermatol. 1981 Dec;5(6):689-95. doi: 10.1016/s0190-9622(81)70130-0.